


Readministration afatinib study

非小細胞肺癌患者



Conclusion EGFR-TKI readministration with afatinib for sensitive EGFR-mutant NSCLC without T790M after resistance to a first- or second-generation EGFR-TKI yielded modest activity with tolerable toxicity. It might be one of the treatment options in patients who do not possess T790M tumors, although further studies in this patient setting are warranted.





Fig. 2 Progression-free survival (**a**) and overall survival (**b**) curves for the 12 patients